ESSA Pharma Inc. (EPIX)
NASDAQ
Market Cap
$77.65M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
658 of 954
Rank in Industry
366 of 546
Largest Insider Buys in Sector
EPIX Stock Price History Chart
EPIX Stock Performance
About ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Insider Activity of ESSA Pharma Inc.
Over the last 12 months, insiders at ESSA Pharma Inc. have bought $0 and sold $12.83M worth of ESSA Pharma Inc. stock.
On average, over the past 5 years, insiders at ESSA Pharma Inc. have bought $4.85M and sold $4.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,223 shares for transaction amount of $21,213 was made by Parkinson David Ross (Chief Executive Officer) on 2023‑12‑14.
List of Insider Buy and Sell Transactions, ESSA Pharma Inc.
| 2024-11-01 | Sale | 10 percent owner | 7.88M 19.3487% | $1.53 | $12.02M | +25.00% | ||
| 2024-09-09 | Sale | Chief Operating Officer | 694 0.0016% | $6.00 | $4,164 | -68.50% | ||
| 2024-09-03 | Sale | Chief Operating Officer | 2,082 0.0048% | $6.03 | $12,554 | -68.63% | ||
| 2024-05-06 | Sale | Chief Operating Officer | 694 0.0016% | $6.95 | $4,823 | -23.50% | ||
| 2024-04-05 | Sale | Chief Operating Officer | 694 0.0015% | $7.94 | $5,510 | -34.31% | ||
| 2024-03-05 | Sale | Chief Operating Officer | 694 0.0015% | $8.98 | $6,232 | -35.73% | ||
| 2024-02-06 | Sale | Chief Operating Officer | 72,782 0.2007% | $10.29 | $748,927 | -43.55% | ||
| 2024-02-05 | Sale | Chief Operating Officer | 1,194 0.0031% | $9.58 | $11,440 | -40.31% | ||
| 2024-01-16 | Sale | Chief Operating Officer | 1,718 0.0043% | $10.01 | $17,197 | -34.06% | ||
| 2024-01-05 | Sale | Chief Operating Officer | 699 0.0015% | $6.11 | $4,271 | -2.21% | ||
| 2023-12-14 | Chief Executive Officer | 9,223 0.0081% | $2.30 | $21,213 | +4.17% | |||
| 2023-11-21 | director | 23,259 0.0523% | $5.73 | $133,274 | +7.40% | |||
| 2023-11-03 | director | 16,471 0.0373% | $5.99 | $98,661 | +3.83% | |||
| 2023-11-02 | director | 60,000 0.1371% | $5.35 | $321,000 | +16.45% | |||
| 2022-12-30 | Chief Executive Officer | 3,067 0.0072% | $2.60 | $7,974 | +17.06% | |||
| 2022-12-30 | Chief Financial Officer | 8,302 0.0194% | $2.60 | $21,585 | +17.06% | |||
| 2022-12-22 | Chief Executive Officer | 21,367 0.0493% | $2.39 | $51,067 | +25.11% | |||
| 2022-12-21 | Sale | director | 72,223 0.1656% | $2.41 | $174,401 | +23.01% | ||
| 2022-12-20 | Sale | director | 43,617 0.0986% | $2.53 | $110,351 | +15.75% | ||
| 2022-12-16 | Sale | director | 50,000 0.1156% | $2.67 | $133,500 | +12.21% |
Insider Historical Profitability
<0.0001%
| Virsik Peter | Chief Operating Officer | 8470 0.0191% | $1.75 | 0 | 9 | |
| BIOTECH GROWTH N V | 10 percent owner | 0 0% | $1.75 | 3 | 1 | <0.0001% |
| BB BIOTECH AG | 5879583 13.2516% | $1.75 | 2 | 1 | <0.0001% | |
| BERGER FRANKLIN M | director | 784404 1.7679% | $1.75 | 4 | 5 | <0.0001% |
| Parkinson David Ross | Chief Executive Officer | 65675 0.148% | $1.75 | 4 | 0 | +11.41% |
| Wood David S. | Chief Financial Officer | 33343 0.0751% | $1.75 | 1 | 0 | +17.06% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Bvf Inc Il | $74.28M | 19.72 | 8.75M | 0% | +$0 | 0.54 | |
| Bellevue Group | $66.98M | 17.78 | 7.89M | -0.11% | -$76,410.00 | 1.03 | |
| Morgan Stanley | $35.48M | 9.42 | 4.18M | -0.19% | -$68,174.70 | <0.01 | |
| Soleus Capital Management, L.P. | $30.48M | 8.09 | 3.59M | -17.05% | -$6.27M | 0.13 | |
| PFM Health Sciences | $25.3M | 6.72 | 2.98M | -8.65% | -$2.39M | 0.7 | |
| RTW Investments, LP | $19.52M | 5.18 | 2.3M | 0% | +$0 | 0.29 | |
| Adage Capital Partners Gp L L C | $13.42M | 3.56 | 1.58M | +39.13% | +$3.77M | 0.02 | |
| Janus Henderson | $9.98M | 2.65 | 1.18M | +7.87% | +$728,102.43 | 0.01 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $7.74M | 2.06 | 911,820 | +155.77% | +$4.71M | 0.75 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $5.75M | 1.53 | 677,005 | 0% | +$0 | 0.15 | |
| Schonfeld Group | $3.13M | 0.83 | 368,500 | New | +$3.13M | 0.02 | |
| Parkman Healthcare Partners Llc | $2.14M | 0.57 | 251,695 | New | +$2.14M | 0.27 | |
| CIBC World Markets | $686,000.00 | 0.18 | 80,857 | -27.61% | -$261,675.53 | <0.01 | |
| D. E. Shaw & Co. | $552,538.00 | 0.15 | 65,081 | -67.4% | -$1.14M | <0.01 | |
| American Century Investments | $392,034.00 | 0.1 | 46,176 | +130.37% | +$221,860.54 | <0.0001 | |
| Citadel Advisors LLC | $310,038.00 | 0.08 | 36,518 | -86.15% | -$1.93M | <0.0001 | |
| Royal Bank of Canada | $262,000.00 | 0.07 | 30,775 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $228,024.00 | 0.06 | 26,858 | 0% | +$0 | <0.0001 | |
| Millennium Management LLC | $119,301.00 | 0.03 | 14,052 | New | +$119,301.00 | <0.0001 | |
| Advisor Group Holdings Inc | $50,940.00 | 0.01 | 6,000 | 0% | +$0 | <0.0001 | |
| BlackRock | $47,620.00 | 0.01 | 5,609 | -26.94% | -$17,557.17 | <0.0001 | |
| Simplex Trading Llc | $36,000.00 | 0.01 | 4,329 | +3.52% | +$1,222.45 | <0.01 | |
| UBS | $30,785.00 | 0.01 | 3,626 | -25.92% | -$10,773.90 | <0.0001 | |
| Cibc Private Wealth Group Llc | $21,050.00 | 0.01 | 2,500 | New | +$21,050.00 | <0.0001 | |
| Laurel Wealth Advisors Llc | $5,094.00 | <0.01 | 600 | 0% | +$0 | <0.01 | |
| JPMorgan Chase | $178.00 | <0.01 | 21 | 0% | +$0 | <0.0001 | |
| Toronto-Dominion Bank | $408.00 | <0.01 | 48 | 0% | +$0 | <0.0001 | |
| Bank of America | $68.00 | <0.01 | 8 | 0% | +$0 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.